Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ENTRANCE: VH3810109 With or Without Fostemsavir in Combination With INSTI-based ART on Viral Reservoir in Adults Living With HIV-1
NCT07053384Phase 1Active, not recruiting
- Sponsor
- ViiV Healthcare
- Start
- Jul 2025
- Primary completion
- Jan 2027
- Modality
- Antibody Conjugates, Engineered Antibody Formats, Anti-infectious Disease mAbs
- Countries
- 6
01
Overview
Phase 1, randomised, open-label trial of VH3810109 in human immunodeficiency virus infection (HIV) (4 arms), sponsored by ViiV Healthcare. Primary endpoint: Change from baseline in cell-associated HIV-1 RNA transcripts per million CD4+ T cells at Month 12. Started Jul 2025; status: active, not recruiting.
02
Drugs
VH3810109
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT07053384.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07053384.